Today a federal court jury in Minneapolis, Minnesota determined that Johnson
& Johnson failed to adequately warn of the risks of tendon rupture
in users of its antibiotic, Levaquin. This is the first trial involving
claims that Levaquin carries a higher risk of tendon damage and rupture.
There are approximately 2,600 Levaquin lawsuits on file.
The jury assigned 75% of the liability to Otho-McNeil-Janssen (Johnson
& Johnson's pharmaceutical unit), 10% to the Plaintiff and 15%
to Plaintiff's doctor. The jury is still considering Plaintiff's
claim for punitive damages.
Levaquin, an antibiotic belonging to the class of antibiotics called fluoroquinolones,
is marketed in the United States by Johnson & Johnson and its pharmaceutical
unit, Ortho-McNeil-Janssen. In 2008, the FDA required that Levaquin and
other fluoroquinolones carry a warning that these drugs carried an increased
risk of tendon damage and tendon rupture.
Plaintiffs allege that Johnson & Johnson aggressively marketed the
drug, prescribed more than 430 million times worldwide, and downplayed
the risk of tendon damage and tendon rupture. J&J denies that Levaquin
caused Plaintiff's injury or that it concealed any relevant safety